Increasing incidence of thyroid cancer in the United States, 1973-2002
- PMID: 16684987
- DOI: 10.1001/jama.295.18.2164
Increasing incidence of thyroid cancer in the United States, 1973-2002
Abstract
Context: Increasing cancer incidence is typically interpreted as an increase in the true occurrence of disease but may also reflect changing pathological criteria or increased diagnostic scrutiny. Changes in the diagnostic approach to thyroid nodules may have resulted in an increase in the apparent incidence of thyroid cancer.
Objective: To examine trends in thyroid cancer incidence, histology, size distribution, and mortality in the United States.
Methods: Retrospective cohort evaluation of patients with thyroid cancer, 1973-2002, using the Surveillance, Epidemiology, and End Results (SEER) program and data on thyroid cancer mortality from the National Vital Statistics System.
Main outcome measures: Thyroid cancer incidence, histology, size distribution, and mortality.
Results: The incidence of thyroid cancer increased from 3.6 per 100,000 in 1973 to 8.7 per 100,000 in 2002-a 2.4-fold increase (95% confidence interval [CI], 2.2-2.6; P<.001 for trend). There was no significant change in the incidence of the less common histological types: follicular, medullary, and anaplastic (P>.20 for trend). Virtually the entire increase is attributable to an increase in incidence of papillary thyroid cancer, which increased from 2.7 to 7.7 per 100,000-a 2.9-fold increase (95% CI, 2.6-3.2; P<.001 for trend). Between 1988 (the first year SEER collected data on tumor size) and 2002, 49% (95% CI, 47%-51%) of the increase consisted of cancers measuring 1 cm or smaller; 87% (95% CI, 85%-89%) consisted of cancers measuring 2 cm or smaller. Mortality from thyroid cancer was stable between 1973 and 2002 (approximately 0.5 deaths per 100,000).
Conclusions: The increasing incidence of thyroid cancer in the United States is predominantly due to the increased detection of small papillary cancers. These trends, combined with the known existence of a substantial reservoir of subclinical cancer and stable overall mortality, suggest that increasing incidence reflects increased detection of subclinical disease, not an increase in the true occurrence of thyroid cancer.
Comment in
-
Managing small thyroid cancers.JAMA. 2006 May 10;295(18):2179-82. doi: 10.1001/jama.295.18.2179. JAMA. 2006. PMID: 16684990 No abstract available.
-
Changing incidence of thyroid cancer.JAMA. 2006 Sep 20;296(11):1350; author reply 1350. doi: 10.1001/jama.296.11.1350-a. JAMA. 2006. PMID: 16985224 No abstract available.
Similar articles
-
Incidence and histological patterns of thyroid cancer in Sri Lanka 2001-2010: an analysis of national cancer registry data.BMC Cancer. 2018 Feb 7;18(1):163. doi: 10.1186/s12885-018-4083-5. BMC Cancer. 2018. PMID: 29415672 Free PMC article.
-
Current thyroid cancer trends in the United States.JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):317-22. doi: 10.1001/jamaoto.2014.1. JAMA Otolaryngol Head Neck Surg. 2014. PMID: 24557566
-
Thyroid cancer: trends in incidence, mortality and clinical-pathological patterns in Zhejiang Province, Southeast China.BMC Cancer. 2018 Mar 15;18(1):291. doi: 10.1186/s12885-018-4081-7. BMC Cancer. 2018. PMID: 29544469 Free PMC article.
-
Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study.Endocr Pathol. 2007 Spring;18(1):1-7. doi: 10.1007/s12022-007-0002-z. Endocr Pathol. 2007. PMID: 17652794 Review.
-
Incidental thyroid nodules and thyroid cancer: considerations before determining management.JAMA Otolaryngol Head Neck Surg. 2015 Jun;141(6):566-72. doi: 10.1001/jamaoto.2015.0647. JAMA Otolaryngol Head Neck Surg. 2015. PMID: 25928353 Review.
Cited by
-
Candidate agents for papillary thyroid cancer identified by gene expression analysis.Pathol Oncol Res. 2013 Jul;19(3):597-604. doi: 10.1007/s12253-013-9625-1. Epub 2013 Mar 22. Pathol Oncol Res. 2013. PMID: 23519608
-
CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy.Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):61-71. doi: 10.1007/s00259-012-2242-5. Epub 2012 Oct 19. Eur J Nucl Med Mol Imaging. 2013. PMID: 23081821 Free PMC article.
-
The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer.Cancer. 2013 Jan 15;119(2):259-65. doi: 10.1002/cncr.27721. Epub 2012 Jun 28. Cancer. 2013. PMID: 22744940 Free PMC article.
-
Unusual locations for differentiated thyroid cancer nodal metastasis.World J Otorhinolaryngol Head Neck Surg. 2020 Jun 16;6(3):176-181. doi: 10.1016/j.wjorl.2020.01.011. eCollection 2020 Sep. World J Otorhinolaryngol Head Neck Surg. 2020. PMID: 33073213 Free PMC article. Review.
-
Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer.J Transl Med. 2016 Jul 7;14(1):204. doi: 10.1186/s12967-016-0958-x. J Transl Med. 2016. PMID: 27387551 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical